Cognition Therapeutics Inc (CGTX) concluded trading on Wednesday at a closing price of $0.50, with 41.45 million shares of worth about $20.73 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -32.93% during that period and on Wednesday the price saw a loss of about -4.18%. Currently the company’s common shares owned by public are about 40.81M shares, out of which, 33.67M shares are available for trading.
Stock saw a price change of -21.43% in past 5 days and over the past one month there was a price change of -30.28%. Year-to-date (YTD), CGTX shares are showing a performance of -29.42% which decreased to -75.25% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.34 but also hit the highest price of $2.95 during that period. The average intraday trading volume for Cognition Therapeutics Inc shares is 7.02 million. The stock is currently trading -20.48% below its 20-day simple moving average (SMA20), while that difference is down -25.59% for SMA50 and it goes to -48.95% lower than SMA200.
Cognition Therapeutics Inc (NASDAQ: CGTX) currently have 40.81M outstanding shares and institutions hold larger chunk of about 12.30% of that.
The stock has a current market capitalization of $20.56M and its 3Y-monthly beta is at 1.01. It has posted earnings per share of -$0.96 in the same period. It has Quick Ratio of 2.11 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CGTX, volatility over the week remained 13.83% while standing at 9.77% over the month.
Stock’s fiscal year EPS is expected to rise by 4.46% while it is estimated to increase by 25.76% in next year. EPS is likely to grow at an annualized rate of 9.38% for next 5-years, compared to annual growth of -21.09% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by B. Riley Securities on December 19, 2024 offering a Buy rating for the stock and assigned a target price range of between $1 and $1.50 to it. On November 03, 2021, Oppenheimer Initiated their recommendations, while on November 03, 2021, B. Riley Securities Initiated their ratings for the stock with a price target of $27.
